文献速递免疫规划慢病防控与筛查

比较中枢神经系统脱髓鞘疾病与其他神经系统疾病患者接种COVID-19疫苗后的转归

Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders.
PubMed 文献 · Vaccine · 2024-06-16

在伊朗伊斯法罕开展的横断面研究纳入1307例患者(738例多发性硬化、96例视神经脊髓炎谱系疾病、76例临床孤立综合征、397例其他神经系统疾病),比较接种COVID-19疫苗后的感染与不良事件。多发性硬化(OR=3.86,p<0.001)和视神经脊髓炎谱系疾病(OR=2.77,p=0.015)患者接种后COVID-19感染 odds 显著高于其他神经系统疾病患者;除第二剂次视神经脊髓炎谱系疾病患者不良事件 odds 低于其他神经系统疾病患者(OR=0.55,p=0.019)外,各组不良事件率无显著差异。

要点

  • 多发性硬化患者接种后COVID-19感染 odds 显著高于其他神经系统疾病患者(OR=3.86,p<0.001)。
  • 视神经脊髓炎谱系疾病患者接种后感染 odds 亦显著高于其他神经系统疾病患者(OR=2.77,p=0.015)。
  • 除第二剂次视神经脊髓炎谱系疾病患者不良事件 odds 较低(OR=0.55,p=0.019)外,各组不良事件率无显著差异。

核心结论

  • 多发性硬化和视神经脊髓炎谱系疾病患者接种COVID-19疫苗的安全性与其他神经系统疾病患者相似,但接种后COVID-19感染率似乎更高。
  • 作者认为这些发现凸显了定期血清学监测的重要性以及多发性硬化和视神经脊髓炎谱系疾病患者补充疫苗剂量的潜在优势。

研究设计与样本

  • 在伊朗伊斯法罕开展的横断面研究,收集2021年9月至2022年9月多发性硬化、视神经脊髓炎谱系疾病和其他神经系统疾病患者的基线数据及COVID-19感染与疫苗接种信息。
  • 其他神经系统疾病患者中主要的神经系统疾病包括头痛、癫痫和帕金森病。
  • 采用逻辑回归分析比较不同患者组的COVID-19疫苗接种转归,报告OR及95%CI。
  • 共纳入1307例参与者,其中多发性硬化738例、视神经脊髓炎谱系疾病96例、临床孤立综合征76例、其他神经系统疾病397例。

主要发现

  • 多发性硬化患者接种后COVID-19感染的 odds 显著高于其他神经系统疾病患者(OR=3.86,p<0.001)。
  • 视神经脊髓炎谱系疾病患者接种后COVID-19感染的 odds 显著高于其他神经系统疾病患者(OR=2.77,p=0.015)。
  • 既往COVID-19感染史和接种疫苗类型与多发性硬化和视神经脊髓炎谱系疾病患者接种后COVID-19感染可能性无显著关联(所有p>0.05)。
  • 多发性硬化、视神经脊髓炎谱系疾病和其他神经系统疾病患者不良事件率无显著差异,除外第二剂次视神经脊髓炎谱系疾病患者不良事件 odds 低于其他神经系统疾病患者(OR=0.55,p=0.019)。

临床怎么用

  • 作者认为定期血清学监测对多发性硬化和视神经脊髓炎谱系疾病患者具有重要性。
  • 作者认为多发性硬化和视神经脊髓炎谱系疾病患者补充疫苗剂量可能具有潜在优势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination constitutes a crucial preventive measure against COVID-19 infection. Concerns have been raised regarding the efficacy of vaccines in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients due to various immunomodulatory medications and potential adverse events that may impact neurological function. This study aimed to explore the implications of COVID-19 vaccination within MS and NMSOD patients and compare it with other neurological disorders (OND). METHOD: In this cross-sectional study conducted in Isfahan, Iran, baseline data and information on COVID-19 infections and vaccinations were collected from MS, NMOSD, and OND patients between September 2021 and September 2022. The predominant neurological disorders identified among OND patients encompassed headache, epilepsy, and Parkinson's disease. Logistic regression analysis was employed to compare COVID-19 vaccination outcomes among different patient groups, presenting odds ratios (OR) with 95% confidence intervals (CI). RESULTS: The study included 1,307 participants, with 738 having MS, 96 having NMOSD, 76 having clinically isolated syndrome (CIS), and 397 having OND. Significantly higher odds of post-vaccination COVID-19 infection were detected in MS (OR = 3.86, p < 0.001) NMOSD (OR = 2.77, p = 0.015) patients than OND patients. The prior history of COVID-19 infection and the type of vaccine administered did not demonstrate significant associations with the likelihood of post-vaccination COVID-19 infection in MS and NMOSD patients (p > 0.05 for all). There were no significant differences in the rates of adverse events in MS, NMOSD, and OND patients, except the second dose, where NMOSD patients had lower odds than OND patients (OR = 0.55, p = 0.019). CONCLUSION: Although the safety profile of COVID-19 vaccination in MS and NMOSD was similar to that in OND, the rates of post-vaccination COVID-19 infection in MS and NMOSD seem higher than OND. These findings highlight the importance of regular serological monitoring and the potential advantages of supplementary vaccine doses in MS and NMOSD patients.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yazdan Panah M, Vaheb S, Mokary Y, et al. Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders. Vaccine. 2024. PMID: 38886142. doi:10.1016/j.vaccine.2024.06.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。